Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients

Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2011-11, Vol.4 (3), p.531-533
Main Authors: Boyle, H., Négrier, S.
Format: Article
Language:English
Subjects:
Bevacizumab
Combination
Published: November 2011
Renal carcinoma
Temsirolimus
Treatment
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone.
ISSN:1662-6575
1662-6575
DOI:10.1159/000334581